Form 8-K KERYX BIOPHARMACEUTICALS For: Nov 06
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Roth Capital Remains Positive on Keryx (KERX) Following Q3 Results, Update
November 6, 2014 11:27 AM ESTRoth Capital affirmed Keryx Biopharma (Nasdaq: KERX) at Buy with a price target of $32 following Q3 results reported earlier Thursday. Keryx posted Q3 loss of $0.38 per share, while Roth was looking for a loss of just $0.24 per share.
Analyst Joseph Pantginis commented, The third quarter represented a successful period for KERX, with the approval of Ferric Citrate in September 2014 for the control of serum phosphorus... More
